Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Thyroid Gland Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 9 active trials
5 drugs · 3 active trials
10 drugs · 42 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Trametinib | Approved | Phase 3 | 10 | 3 | 2 | 16 | 2 | US | May 29, 2013 | 2011-10 |
| Dabrafenib | Approved | Phase 3 | 8 | 3 | 2 | 12 | 2 | US | May 29, 2013 | 2012-07 |
| Cabozantinib | Approved | Phase 4 | 7 | 2 | 4 | 17 | 3 | EU, US | Nov 29, 2012 | 2005-09 |
| Selpercatinib | Approved | Phase 3 | 6 | 1 | 1 | 6 | 4 | US | May 8, 2020 | May 2, 2017 |
| Lenvatinib | Approved | Phase 4 | 4 | 2 | 1 | 17 | 1 | US | Feb 13, 2015 | Nov 6, 2008 |
| Vandetanib | Approved | Phase 4 | 2 | 1 | 4 | 12 | 2 | EU, US | Apr 6, 2011 | 2004-11 |
| Sorafenib | Approved | Phase 2 | 2 | 1 | 0 | 8 | 1 | US | Dec 1, 2005 | 2006-02 |
| Pralsetinib | Approved | Phase 4 | 2 | 2 | 1 | 4 | 1 | US | Sep 4, 2020 | Mar 17, 2017 |
| Thyrotropin Alfa | Approved | Phase 2 | 1 | 1 | 0 | 2 | 4 | EU, US | Nov 30, 1998 | May 20, 2014 |
| Sorafenib Tosylate | Approved | Phase 2 | 0 | 0 | 0 | 4 | 1 | US | Dec 1, 2005 | 2004-10 |
| Sunitinib | Phase 4 | Phase 4 | 1 | 0 | 0 | 6 | 0 | — | — | Aug 29, 2006 |
| Palbociclib | Phase 4 | Phase 4 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Mitoxantrone | Phase 4 | Phase 4 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 1, 2026 |
| Pazopanib | Phase 4 | Phase 4 | 0 | 0 | 0 | 5 | 0 | — | — | Feb 22, 2008 |
| Olaparib | Phase 4 | Phase 4 | 0 | 0 | 0 | 1 | 0 | — | — | 2024-05 |
| Vemurafenib | Phase 3 | Phase 3 | 4 | 2 | 1 | 7 | 0 | — | — | Nov 7, 2012 |
| Cobimetinib | Phase 3 | Phase 3 | 3 | 2 | 1 | 3 | 0 | — | — | Jul 27, 2017 |
| Paclitaxel | Phase 3 | Phase 3 | 2 | 0 | 1 | 6 | 0 | — | — | 2007-08 |
| Metformin | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2010-04 |
| Carboplatin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2007-08 |
| Nivolumab | Phase 2 | Phase 2 | 7 | 0 | 0 | 8 | 0 | — | — | Aug 17, 2015 |
| Pembrolizumab | Phase 2 | Phase 2 | 6 | 0 | 0 | 12 | 0 | — | — | Dec 18, 2015 |
| Cyclophosphamide | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Mar 2, 2015 |
| Fludarabine | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Mar 2, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Jan 30, 2017 |
| Binimetinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Everolimus | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2004-12 |
| Cetuximab | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Oct 16, 2012 |
| Dabrafenib/Trametinib Regimen | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Dec 30, 2020 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | May 31, 2023 |
| Entrectinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 19, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 27, 2017 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Sep 13, 2024 |
| Bevacizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2006-12 |
| Docetaxel | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2006-12 |
| Durvalumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 25, 2017 |
| Aldesleukin | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Mar 2, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2015-07 |
| Tipifarnib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | May 13, 2015 |
| Tislelizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 12, 2021 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Oct 1, 2020 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Atezolizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 27, 2017 |
| Axitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 14, 2026 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Carboplatin/Paclitaxel Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2024 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.